唑来磷酸联合芳香化酶抑制剂治疗绝经后乳腺癌骨转移的疗效观察

Effect of zoledronic acid combined with aromatizing enzyme inhibitors in the treatment for post-menopause breast cancer patients with bone metastasis

目的观察唑来磷酸联合芳香化酶抑制剂治疗绝经后乳腺癌骨转移的临床疗效。方法将48例绝经后乳腺癌骨转移伴有不同程度骨痛患者随机分为两组:观察组24例,应用唑来磷酸联合芳香化酶抑制剂治疗;对照组24例,应用唑来磷酸或来曲唑治疗,观察骨转移灶的变化及止痛效果。结果观察组24例患者骨转移灶有效率54.17%,止痛总有效率91.67%;对照组24例患者骨转移灶有效率8.33%,止痛总有效率70.83%,观察组明显优于对照组(P<0.05)。结论唑来磷酸联合芳香化酶抑制剂是一种有效治疗绝经后乳腺癌骨转移灶的临床方法,且对骨转移所致的疼痛止痛效果确切,值得临床推广。

Objective To observe the clinical efficacy of zoledronic acid combined with aromatizing enzymeon post - menopause breast cancer patients with bone metastasis. Methods Totally 48 cases of postmenopausal breast cancer patients with bone metastasis andfeh boneache were randomly divided into observation group （ n = 24） and control group （ n = 24）, patients in observation group received the treatment of zoledronic acid combined with aromatizing enzyme inhibitors, while the patients in control group received the treatment of zoledronic acid or letrozole. The clinical efficacy such asmetastasis and pain were observed and analyzed. Results The reduction rate of bone metastasis in observation group （54. 17% ） was significantly higher than that of control group （8.33%）, the control rate of pain in observation group （91.67%） was higher than that of control group （70.83%） （ P 〈 0. 05 ）. Conclusions Zoledronic acid combined with aromatizing enzyme inhibitors was effective in the treatmenton postmenopausal breast cancer with bone metastasis, and was helpful for reducing boneache, worthy of clinical popularization.